CTOs on the Move

WHPM Biotech

www.whpm.com

 
WHPM Biotech is a El Monte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.whpm.com
  • 9662 Telstar Ave
    El Monte, CA USA 91731
  • Phone: 626.443.8480

Executives

Name Title Contact Details

Similar Companies

Kansas Bioscience Organization

Kansas Bioscience Organization is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical corporation based in Indianapolis, Indiana, with a history of nearly 150 years. Founded in 1876 by Colonel Eli Lilly, the company has grown to become one of the largest pharmaceutical enterprises in the world, employing over 42,900 people as of 2023. Lilly focuses on biomedical research, drug discovery, and manufacturing, with a diverse portfolio that includes treatments for diabetes, oncology, neuroscience, and immunology. Lilly pioneered the first commercially available insulin product in 1923 and continues to innovate with modern offerings like Trulicity and Mounjaro for diabetes management. The company also develops drugs such as Verzenio for breast cancer and Zyprexa for psychiatric disorders. With a strong emphasis on research and development, Lilly is recognized for its commitment to improving drug accessibility and patient care through partnerships with healthcare providers and systems worldwide.

Optimum Outcomes

Optimum Outcomes is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ohana Biosciences

Ohana is pioneering a new frontier in reproductive medicine. Built upon a world-leading understanding of sperm biology, Ohana has created a best-in-class proprietary platform with broad applications across reproductive medicine.

Principia Biopharma

Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.